Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials
Blood pressure lowering is an effective strategy for preventing cardiovascular events among people with moderately reduced eGFR. There is little evidence from these overviews to support the preferential choice of particular drug classes for the prevention of cardiovascular events in chronic kidney disease. Evidence Updates
Psychological interventions for needle-related procedural pain and distress in children and adolescents
Overall, there is strong evidence supporting the efficacy of distraction and hypnosis for needle-related pain and distress in children and adolescents, with no evidence currently available for preparation and information or both, combined CBT, parent coaching plus distraction, suggestion, or virtual reality. Additional research is needed to further assess interventions that have only been investigated in one RCT to date (that is, memory alteration, parent positioning plus distraction, blowing out air, and distraction plus suggestion). There are continuing issues with the quality of trials examining psychological interventions for needle-related pain and distress. Uman LS, Birnie KA, Noel M, Parker JA, Chambers CT, McGrath PJ, Kisely SR. Cochrane Database Syst Rev. 2013 Oct 10;10:CD005179. [Epub ahead of print] PMID: 24108531
Integrated disease management interventions for patients with chronic obstructive pulmonary disease
In these COPD participants, IDM not only improved disease-specific QoL and exercise capacity, but also reduced hospital admissions and hospital days per person. Kruis AL, Smidt N, Assendelft WJ, Gussekloo J, Boland MR, Rutten-van Mölken M, Chavannes NH. Cochrane Database Syst Rev. 2013 Oct 10;10:CD009437. [Epub ahead of print] PMID: 24108523
A systematic review and meta-analysis of the evidence base for add-on treatment for patients with major depressive disorder who have not responded to antidepressant treatment: A European perspective
Add-on therapies reviewed were antidepressants, quetiapine XR, lithium, and S-adenosyl-l-methionine (SAMe). Seven RCTs that reported response and remission in a way that allowed quantitative analysis were included in this meta-analysis. Comparison of the different drug classes indicated that most interventions had similar efficacy. The likelihood of response was significantly greater with SAMe versus placebo and lithium and with quetiapine XR versus placebo. Most add-on interventions demonstrated comparable efficacy in patients with MDD and an inadequate response to initial antidepressants. However, there is currently a paucity of high-quality data regarding the use of add-on treatments in patients with MDD who are inadequate responders to antidepressants, with quetiapine XR presenting the most comprehensive evidence base to date. Turner P, Kantaria R, Young AH. Psychopharmacol. 2013 Oct 9. [Epub ahead of print] PMID: 24108407
A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction In conclusion, azilsartan therapy appears to provide a greater reduction in BP than control therapy in patients with hypertension. Takagi H, Mizuno Y, Niwa M, Goto SN, Umemoto T. Hypertens Res. 2013 Oct 10. [Epub ahead of print] PMID: 24108238
No comments:
Post a Comment